Bangkok, 21st June 2016 – Roche
Thailand Ltd., led by Mr. Philippe Meyer, General Manager (1st from left) and Roche Diagnostics (Thailand) Ltd., led by Pichetpong Srisuwankul (1st from right), Managing
Director, and employees held its annual ‘Roche Children’s Walk’
for 2016 and donated funds raised in support for deaf student’s
education to Setsathian School for the Deaf under the Royal Patronage of
His Royal highness Crown Prince Maha Vajiralongkorn,
represented by Dr Panadda Wongchanta (2nd from left), Director. On this occasion, Roche executives and employees also planted
homegrown vegetables in ‘Sufficient Herb Garden’ to support child development and learning.
‘Roche Children’s Walk’
is an annual global CSR event that marks its 13th year in 2016. With a concept of ‘Walking today for a better tomorrow’,
the program emphasizes the business’ determination
in supporting youth, the foundation of a country. Every year in June,
Roche’s employees around the world will raise funds internally from
various fundraising activities and donate the funds to both unprivileged
children in Malawi, South Africa, and all countries
where Roche has operations in, including Thailand. To date, ‘Roche Children’s Walk’
has supported the construction of seven orphan centers, served six
million nutritious meals, trained 560 teachers a year and supported
17,000 children. Since 2003, over
150,000 Roche employees have walked at 141 sites, raising over 12.5
million CHF (456 million THB) to date.
About Roche
Roche is a global pioneer in pharmaceuticals and
diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology
and diseases of the central nervous system. Roche is also the world
leader in in vitro diagnostics and tissue-based cancer diagnostics, and a
frontrunner in diabetes management. The combined
strengths of pharmaceuticals and diagnostics under one roof have made
Roche the leader in personalised healthcare – a strategy that aims to
fit the right treatment to each patient in the best possible way.
Founded in 1896, Roche continues to search for
better ways to prevent, diagnose and treat diseases and make a
sustainable contribution to society. Twenty-nine medicines developed
by Roche are included in the World Health Organisation Model Lists of
Essential Medicines, among them life-saving antibiotics, antimalarials
and cancer medicines. Roche has been recognised as the Group Leader in
sustainability within the Pharmaceuticals, Biotechnology
& Life Sciences Industry seven years in a row by the Dow Jones
Sustainability Indices.
The Roche Group, headquartered in Basel,
Switzerland, is active in over 100 countries and in 2015 employed more
than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion
in R&D and posted sales of CHF 48.1 billion. Genentech, in the
United States, is a wholly owned member of the Roche Group. Roche is the
majority shareholder in Chugai Pharmaceutical, Japan. For more
information, please visit
www.roche.com.
